|
|
|
Welcome!
The Caring for Carcinoid Foundation is the leading 501(c)(3) nonprofit dedicated to discovering a cure for carcinoid cancer.
|
| NANCY O'HAGAN RECEIVES "40 UNDER 40" AWARD |
|
 Award from the Boston Business Journal
Nancy O'Hagan received the "40 Under 40" award from the Boston Business Journal. The award ceremony will be held on October 11, 2007:
"Join us for a special reception and awards presentation as we recognize Greater Boston's next generation of business leaders and innovators. The Boston Business Journal is honoring 40 outstanding professionals under the age of 40 for their business success and community contributions.
Come meet and congratulate Boston's rising stars, and network with former 40 Under 40 awardees and other key area business leaders. This prestigious event will be held at the Marriott Boston Copley Hotel, Thursday, October 11th, 6:00-9:00pm."
|
| NANCY O'HAGAN WRITES NEW BLOG |
|
 "100 Years+ and So What?"
Nancy O'Hagan, CFCF Founder and President, wrote a new blog. It begins:
"Hi Everyone!
Congratulations-this month will be a terrific month for carcinoid and related neureondocrine tumor patients! The NIH/NCI will be hosting the first-ever Carcinoid Summit as a result of language in a House Report that accompanied a House Bill sponsored by Congressman Ralph Regula." (continued)
|
| DR. MEYERSON ISSUES 2007 PROGRESS REPORT |
|
| CFCF-funded researcher at Dana-Farber Cancer Institute
Dr. Matthew Meyerson at Dana-Farber Cancer Institute issued his 2007 Progress Report.
The overall goal of Dr. Meyerson's project is to build on his previous discovery that the menin tumor suppressor protein is coupled to histone methylase activity that regulates histone H3 lysine 4 methylation. This result suggests that tumors lacking the MEN1 gene may have defective histone methylation.
Read Dr. Meyerson's 2007 Progress Report |
| CFCF-FUNDED RESEARCH APPEARS IN CLINICAL CANCER RESEARCH |
|
 Peer-reviewed publication
An article entitled, "The Development and Characterization of a Human Midgut Carcinoid Cell Line" appeared in the peer-reviewed journal, Clinical Cancer Research. This article recognizes the Caring for Carcinoid Foundation for its research funding support.
The authors are George Van Buren II, Asif Rashid, Anthony D. Yang, Eddie K. Abdalla, Michael J. Gray, Wenbiao Liu, Ray Somcio, Fan Fan, E. Ramsay Camp, James C. Yao, and Lee M. Ellis.
The authors state:
"Gastrointestinal neuroendocrine tumors (NET) are rare heterogeneous tumors that hypersecrete neuropeptides. The scarcity of good gastrointestinal NET models has limited the ability to study potential therapeutic agents. We describe and characterize the establishment of a human midgut carcinoid tumor cell line carcinoid tumor 2 (CNDT2). ...
The establishment of this human midgut carcinoid tumor cell line may serve as a useful model system for studying cell biology and novel targeted agents in preclinical models."
|
| CFCF-FUNDED RESEARCH APPEARS IN PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES |
|
 Peer-reviewed publication
An article entitled, "Enteroendocrine precursors differentiate independently of Wnt and form serotonin expressing adenomas in response to active B-catenin" appeared in the peer-reviewed journal, Proceedings of the National Academy of Sciences. This article recognizes the Caring for Carcinoid Foundation for its research funding support.
The authors are Yang Wang, Maryann Giel-Moloney, Guido Rindi, and Andrew B. Leiter.
The authors state:
"These results provide direct evidence that some intestinal lineages are specified independently of the Wnt pathway and may lead to a better understanding of the spectrum of neuroendocrine differentiation frequently seen in human gastrointestinal cancer."
|
|
TEAM CFCF RAISES $250,000 IN 2007 PAN-MASS CHALLENGE |
|
 Record-breaking fundraising for carcinoid research
Team Caring for Carcinoid Foundation completed a highly successful Pan-Mass Challenge on August 4-5, 2007.
Team CFCF raised $250,000. We are grateful that every dollar is matched by the Steve and Caroline Kaufer Foundation--bringing the total to an astonishing $500,000. Every dollar directly funds cutting-edge carcinoid research.
Congratulations, Team CFCF!
|
|
TEAM CFCF IN 2007 CHICAGO MARATHON |
|
| 34 runners projected to raise over $40,000
Team CFCF has an astounding 34 runners entered in the 2007 LaSalle Bank Chicago Marathon on October 7, 2007.
Every dollar raised by Team CFCF directly funds cutting-edge carcinoid research.
Jamie Koch, for example, is running to honor Brad Monks:
"My friend and fraternity brother, Brad Monks, lost his battle with carcinoid in February of this year. Before Brad was diagnosed, I had never heard of carcinoid cancer.
CFCF is the leading non-profit organization dedicated to discovering a cure for carcinoid. As was his nature, Brad threw himself wholeheartedly into fundraising efforts on behalf of CFCF and he was viewed as an inspiration in the carcinoid community.
This is the first year that CFCF is sponsoring a team in the Chicago Marathon and it is my goal to raise awareness and funds for this organization and its mission that meant so much to Brad.
I will be training for this marathon solo, which can be difficult. I would like to think that many of you could serve as my "mental" support team during some of those long training runs, and that, working together, we can reach my stated goal of raising $5,000 (or more) for Brad and CFCF."
Jamie has raised $3,650. Help Jamie reach $5,000!
|
| 5 NEW SURVIVOR STORIES |
|
 CFCF is honored to present Survivor Stories. They reflect remarkable courage and determination.
CFCF posted 5 new Survivor Stories from:
|
| FDA OFFERS $14M TO ORPHAN DRUG RESEARCH |
|
 $200,000-$400,000 per Year Awards Available
The Food and Drug Administration (FDA) announced a new research grant program to support orphan drug research. This program is administered by the FDA's Office of Orphan Products Development (OPD):
"The goal of FDA's OPD grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the product will improve the existing therapy.
Grants will be awarded up to $200,000 or up to $400,000 in total (direct plus indirect) costs per year for up to 4 years.
For FY 2009, the application receipt date is February 6, 2008, and for FY 2010, the application receipt date is February 4, 2009."
|
| NOVARTIS LAUNCHES "CARCINOID LINK" |
|
 Online program for carcinoid patients, families, and friends
Novartis launched "Carcinoid Link", an online program for carcinoid patients, families, and friends. "Carcinoid Link" offers the following:
"Enroll in Carcinoid Link now and you'll receive an important article by Larry Kvols, M.D., designed to help you understand more about the condition.
Simply complete the questionnaire below, and the article will appear on your screen. During the course of your participation in the Carcinoid Link program, you'll receive a series of personalized communications, including E-mails and even webcasts-all offering you valuable information about carcinoid cancer."
|
| DONATE TO CFCF VIA eBAY |
|
 Easy to donate 10%-100% of your sales proceeds
When you sell on eBay, it is easy to donate 10%-100% of your proceeds to the Caring for Carcinoid Foundation (CFCF).
|
| P.S. PRINTS SELLS SUNFLOWER GIFTS |
|
 All profits donated to CFCF
P.S. Prints sells sunflower t-shirts, mugs, postcards, and more.
100% of profits are donated to CFCF and directly support cutting-edge carcinoid research.
| |
|
|
|
